23andMe Holding Co.
NASDAQ:ME

Watchlist Manager
23andMe Holding Co. Logo
23andMe Holding Co.
NASDAQ:ME
Watchlist
Price: 0.6063 USD -21.26% Market Closed
Market Cap: $88.5m

Net Margin

-183.4%
Current
Improving
by 13.8%
vs 3-y average of -197.2%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-183.4%
=
Net Income
$-382.9m
/
Revenue
$208.8m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-183.4%
=
Net Income
$-382.9m
/
Revenue
$208.8m

Peer Comparison

Country Company Market Cap Net
Margin
US
23andMe Holding Co.
NASDAQ:ME
88.5m USD
Loading...
US
CVS Health Corp
NYSE:CVS
90.2B USD
Loading...
US
Cigna Group
XMUN:CGN
63B EUR
Loading...
US
Cigna Corp
NYSE:CI
72.3B USD
Loading...
DE
Fresenius SE & Co KGaA
XETRA:FRE
27.6B EUR
Loading...
DE
Fresenius Medical Care AG
XMUN:FME
21.8B EUR
Loading...
US
Laboratory Corporation of America Holdings
NYSE:LH
22.3B USD
Loading...
US
Quest Diagnostics Inc
NYSE:DGX
20.4B USD
Loading...
US
Guardant Health Inc
NASDAQ:GH
14.3B USD
Loading...
DE
Fresenius Medical Care AG & Co KGaA
XETRA:FME
10.8B EUR
Loading...
AU
Sonic Healthcare Ltd
ASX:SHL
11.1B AUD
Loading...

Market Distribution

Lower than 87% of companies in the United States of America
Percentile
13th
Based on 15 072 companies
13th percentile
-183.4%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

23andMe Holding Co.
Glance View

Market Cap
88.5m USD
Industry
Health Care

23andMe Holding Co. is consumer genetics and research company, which engages to help people access, understand, and benefit from the human genome. The company is headquartered in South San Francisco, California. The company went IPO on 2020-10-06. The firm offers direct-to-consumer genetic testing and personalized information about genetic health risks, ancestry, and traits. The firm operates through two segments: Consumer & Research Services and Therapeutics. Its consumer & research services business segment comprises personal genome service (PGS) and research services. Its PGS provides a suite of genetic reports, including information on genetic ancestral origins, personal genetic health risks, rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Company’s therapeutics segment focuses on drug development for discovering and developing therapies to improve patient lives and includes out-licensing of intellectual property. The Company’s programs across therapeutic areas, include oncology, immunology, neurology, metabolic and cardiovascular diseases.

ME Intrinsic Value
Not Available
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-183.4%
=
Net Income
$-382.9m
/
Revenue
$208.8m
What is 23andMe Holding Co.'s current Net Margin?

The current Net Margin for 23andMe Holding Co. is -183.4%, which is above its 3-year median of -197.2%.

How has Net Margin changed over time?

Over the last 3 years, 23andMe Holding Co.’s Net Margin has decreased from -82.7% to -183.4%. During this period, it reached a low of -318.4% on Sep 30, 2024 and a high of -80% on Mar 31, 2022.

Back to Top